

Defensive, innovative, growing: the healthcare sector

In theme 7 of our series, we look at what the healthcare sector has to offer in times of lackluster economic data and falling interest rates.


Investing in the healthcare (HC) sector in a U.S. presidential election year is normally a no-go. To understand why, one first has to know that U.S. companies account for 71% of the MSCI World Healthcare Index market value. And that the U.S. spends more on healthcare per capita, as a percentage of GDP and in absolute terms, than any other country.¹ The U.S. elections are therefore very important for this sector, and often do not bring it good news. The question of how much the sector should contribute to financing new government plans is often at stake. Although the industry is trying to defend itself – it lobbies like no other in the U.S.² – there are limits. The fact that the sector's average operating margin has fallen from over 20% to 14% over the past 30 years, while the S&P 500's operating margin has risen from 12% to 14% over the same period, is likely to be partly due to this (in Europe the margin has fallen from 25% to 16% over the past 20 years).³ However, we think the elections this year will result in less harm for the sector than usual for two reasons: 1. The Democrats, the party that is more critical of the pharmaceutical industry, are already in the White House. 2. Healthcare policy is not the focus of this election campaign for either party.

A number of factors make HC attractive: 1. Innovation. The potential for new products to boost share prices was recently demonstrated by the introduction of anti-obesity drugs, which resulted in a manyfold increase in the share prices of both market leaders.⁴ While that is certainly extraordinary, there are many areas in which markets worth billions of dollars could rapidly develop. For example in cancer, dementia and gene therapies. 2. In addition, AI could advance the sector in many ways, with productivity gains in the development of new drugs, reduced failure rates in clinical trials, and improved diagnostics and support for patient care. 3. The aging society suggests that HC spending will continue to grow disproportionately. 4. Corporate bond yields have been falling again for about two years, which should help smaller and younger companies in particular to raise funds more cheaply.

For shareholders, we believe the sector's combination of defensive qualities and growth potential is particularly appealing. But the former only applies to the sector as a whole. The sector's constituents are subject to the same profit volatility

as cyclical stocks.⁵ Performance is also very heterogeneous: the S&P 500 HC gained 20% over the past 12 months, but the strongest HC stock gained 60%, while the weakest lost 40%.⁶ This reinforces our conviction that stock selection is essential in healthcare. Success or failure at the company level can hinge on one drug.

Relative price and valuation history of HC sector



Sources: Bloomberg Finance L.P., DWS Investment GmbH as of 10/9/24. *S&P500 EW is the equal-weight S&P500

As the chart shows, the U.S. HC sector has mostly performed similarly to the S&P 500. The discrepancy over the last 18 months is mainly due to the strength of the big U.S. tech stocks.⁷ The picture is similar when it comes to valuations. The sector is trading at a slight discount to the overall market and below its historical relative valuation. However, it is trading at a slight premium to the equal-weight market.⁸ In our opinion, this is also justified. The current economic cycle is difficult to grasp. We do not rule out a U.S. recession, and the goods industry is contracting. Then there are the serious geopolitical conflicts. That's why the defensive qualities of healthcare are tempting, even if a major U.S. downturn is not yet visible. At the same time, we expect only low growth in developed markets in the medium term. Here, too, individual healthcare sectors are partly immune, as we expect them to enjoy structural growth. Noushin Irani, DWS Equity Sector Head Healthcare, currently prefers biotech stocks and the major pharmaceuticals.⁹

DWS does not intend to promote a particular outcome to the U.S. election due to take place in November. Readers should, of course, vote in the election as they personally see fit. This information is subject to change at any time, based upon economic, market and other considerations and should not be construed as a recommendation. Past performance is not indicative of future returns. Forecasts are based on assumptions, estimates, opinions and hypothetical models that may prove to be incorrect. Source: DWS Investment GmbH.

Footnotes

Unless otherwise noted, all price and balance-sheet figures are from Bloomberg L.P. as of 10/9/24.

¹ Source: OECD, as of 2022

² Source: Statista. October 2024. Last figures for 2023, when the sector spent USD 740m on lobbying in the US. It has been one of the top three lobbyists since 2000 and has been top of the league since 2016.

³ Data for S&P 500, S&P 500 Healthcare, Stoxx 600 and Stoxx 600 Healthcare. Source: Bloomberg Finance L.P.; as of 10/9/24

⁴ Within five years, the share price of US company Eli Lilly has increased almost ninefold, while that of Danish company Novo Nordisk has increased almost fivefold. Source: Bloomberg L.P. As of: 10/9/24.

⁵ Many stocks in the sector have also seen rising debt levels recently, which has also contributed to higher volatility in earnings and share prices.

⁶ Due to better available data and its dominance, we often refer to the S&P 500 and the S&P 500 Healthcare in this context, but the opinions in the text refer to the global sector.

⁷ The equal-weight S&P 500 reduces the distortions caused by the heavyweights in technology and media stocks.

⁸ The equal-weight S&P 500 valuation is less distorted by single dominant stocks than the market-cap-weighted S&P 500 valuation.

⁹ Within the MSCI World Healthcare, pharmaceuticals account for 42% of the index market value, and biotechnology for 14%. Source: MSCI, as of 10/9/24

Glossary

The [gross domestic product \(GDP\)](#) is the monetary value of all the finished goods and services produced within a country's borders in a specific time period.

The [MSCI AC World Health Care Index](#) captures large- and mid-cap securities across 23 developed- and 26 emerging-markets classified in the Health Care sector.

The [price-to-earnings \(P/E\) ratio](#) compares a company's current share price to its earnings per share.

A [recession](#) is, technically, when an economy contracts for two successive quarters but is often used in a looser way to indicate declining output.

The [S&P 500](#) is an index that includes 500 leading U.S. companies capturing approximately 80% coverage of available U.S. market capitalization.

The [S&P 500 Health Care Index](#) captures the companies listed in the S&P 500 Index from the health care sector.

[Volatility](#) is the degree of variation of a trading-price series over time. It can be used as a measure of an asset's risk.

Important information – EMEA, APAC, LATAM & MENA

DWS is the brand name of DWS Group GmbH & Co. KGaA and its subsidiaries under which they do business. The DWS legal entities offering products or services are specified in the relevant documentation. DWS, through DWS Group GmbH & Co. KGaA, its affiliated companies and its officers and employees (collectively “DWS”) are communicating this document in good faith and on the following basis.

This document is for information/discussion purposes only and does not constitute an offer, recommendation or solicitation to conclude a transaction and should not be treated as investment advice.

This document is intended to be a marketing communication, not a financial analysis. Accordingly, it may not comply with legal obligations requiring the impartiality of financial analysis or prohibiting trading prior to the publication of a financial analysis.

This document contains forward looking statements. Forward looking statements include, but are not limited to assumptions, estimates, projections, opinions, models and hypothetical performance analysis. No representation or warranty is made by DWS as to the reasonableness or completeness of such forward looking statements. Past performance is no guarantee of future results.

The information contained in this document is obtained from sources believed to be reliable. DWS does not guarantee the accuracy, completeness or fairness of such information. All third party data is copyrighted by and proprietary to the provider. DWS has no obligation to update, modify or amend this document or to otherwise notify the recipient in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

Investments are subject to various risks. Detailed information on risks is contained in the relevant offering documents.

No liability for any error or omission is accepted by DWS. Opinions and estimates may be changed without notice and involve a number of assumptions which may not prove valid. DWS does not give taxation or legal advice.

This document may not be reproduced or circulated without DWS’s written authority.

This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, including the United States, where such distribution, publication, availability or use would be contrary to law or regulation or which would subject DWS to any registration or licensing requirement within such jurisdiction not currently met within such jurisdiction. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions.

© 2024 DWS Investment GmbH

Issued in the UK by DWS Investments UK Limited which is authorised and regulated in the UK by the Financial Conduct Authority.

© 2024 DWS Investments UK Limited

In Hong Kong, this document is issued by DWS Investments Hong Kong Limited. The content of this document has not been reviewed by the Securities and Futures Commission.

© 2024 DWS Investments Hong Kong Limited

In Singapore, this document is issued by DWS Investments Singapore Limited. The content of this document has not been reviewed by the Monetary Authority of Singapore.

© 2024 DWS Investments Singapore Limited

In Australia, this document is issued by DWS Investments Australia Limited (ABN: 52 074 599 401) (AFSL 499640). The content of this document has not been reviewed by the Australian Securities and Investments Commission.

© 2024 DWS Investments Australia Limited

For institutional / professional investors in Taiwan:

This document is distributed to professional investors only and not others. Investing involves risk. The value of an investment and the income from it will fluctuate and investors may not get back the principal invested. Past performance is not indicative of future performance. This is a marketing communication. It is for informational purposes only. This document does not constitute investment advice or a recommendation to buy, sell or hold any security and shall not be deemed an offer to sell or a solicitation of an offer to buy any security. The views and opinions expressed herein, which are subject to change without notice, are those of the issuer or its affiliated companies at the time of publication. Certain data used are derived from various sources believed to be reliable, but the accuracy or completeness of the data is not guaranteed and no liability is assumed for any direct or consequential losses arising from their use. The duplication, publication, extraction or transmission of the contents, irrespective of the form, is not permitted.

as of 10/21/24; 103254_1 (10/2024)

Important information – North America

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries, such as DWS Distributors, Inc., which offers investment products, or DWS Investment Management Americas Inc. and RREEF America L.L.C., which offer advisory services.

Companies involved in artificial intelligence and big data face intense competition, may have limited product lines, markets, financial resources and personnel. Artificial intelligence and big data companies are also subject to risks of new technologies and are heavily dependent on patents and intellectual property rights and the products of these companies may face obsolescence due to rapid technological developments. Any mentions of specific properties or securities are for illustrative purposes only and should not be considered a recommendation.

This document has been prepared without consideration of the investment needs, objectives or financial circumstances of any investor. Before making an investment decision, investors need to consider, with or without the assistance of an investment adviser, whether the investments and strategies described or provided by DWS, are appropriate, in light of their particular investment needs, objectives and financial circumstances. Furthermore, this document is for information/discussion purposes only and does not and is not intended to constitute an offer, recommendation or solicitation to conclude a transaction or the basis for any contract to purchase or sell any security, or other instrument, or for DWS to enter into or arrange any type of transaction as a consequence of any information contained herein and should not be treated as giving investment advice. DWS, including its subsidiaries and affiliates, does not provide legal, tax or accounting advice. This communication was prepared solely in connection with the promotion or marketing, to the extent permitted by applicable law, of the transaction or matter addressed herein, and was not intended or written to be used, and cannot be relied upon, by any taxpayer for the purposes of avoiding any U.S. federal tax penalties. The recipient of this communication should seek advice from an independent tax advisor regarding any tax matters addressed herein based on its particular circumstances. Investments with DWS are not guaranteed, unless specified. Although information in this document has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness, and it should not be relied upon as such. All opinions and estimates herein, including forecast returns, reflect our judgment on the date of this report, are subject to change without notice and involve a number of assumptions which may not prove valid.

Investments are subject to various risks, including market fluctuations, regulatory change, counterparty risk, possible delays in repayment and loss of income and principal invested. The value of investments can fall as well as rise and you may not recover the amount originally invested at any point in time. Further-more, substantial fluctuations of the value of the investment are possible even over short periods of time. Further, investment in international markets can be affected by a host of factors, including political or social conditions, diplomatic relations, limitations or removal of funds or assets or imposition of (or change in) exchange control or tax regulations in such markets. Additionally, investments denominated in an alternative currency will be subject to currency risk, changes in exchange rates which may have an adverse effect on the value, price or income of the investment. This document does not identify all the risks (direct and indirect) or other considerations which might be material to you when entering into a transaction. The terms of an investment may be exclusively subject to the detailed provisions, including risk considerations, contained in the Offering Documents. When making an investment decision, you should rely on the final documentation relating to the investment and not the summary contained in this document.

This publication contains forward looking statements. Forward looking statements include, but are not limited to assumptions, estimates, projections, opinions, models and hypothetical performance analysis. The forward looking statements expressed constitute the author's judgment as of the date of this material. Forward looking statements involve significant elements of subjective judgments and analyses and changes thereto and/or consideration of different or additional factors could have a material impact on the results indicated. Therefore, actual results may vary, perhaps materially, from the results contained herein. No representation or warranty is made by DWS as to the reasonableness or completeness of such forward looking statements or to any other financial information contained herein. We assume no responsibility to advise the recipients of this document with regard to changes in our views.

No assurance can be given that any investment described herein would yield favorable investment results or that the investment objectives will be achieved. Opinions expressed herein may differ from the opinions expressed by departments or other divisions or affiliates of DWS. This document may not be reproduced or circulated without our written authority. The manner of circulation and distribution of this document may be restricted by law or regulation in certain countries. This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, including the United States, where such distribution, publication, availability or use would be contrary to law or regulation or which would subject DWS to any registration or licensing requirement within such jurisdiction not currently met within such jurisdiction. Persons into whose possession this document may come are required to inform themselves of, and to observe, such restrictions.

Past performance is no guarantee of future results; nothing contained herein shall constitute any representation or warranty as to future performance. Further information is available upon investor's request. All third party data (such as MSCI, S&P & Bloomberg) are copyrighted by and proprietary to the provider.

For Investors in Canada: No securities commission or similar authority in Canada has reviewed or in any way passed upon this document or the merits of the securities described herein and any representation to the contrary is an offence. This document is intended for discussion purposes only and does not create any legally binding obligations on the part of DWS Group. Without limitation, this document does not constitute an offer, an invitation to offer or a recommendation to enter into any transaction. When making an investment decision, you should rely solely on the final documentation relating to the transaction you are considering, and not the information contained herein. DWS Group is not acting as your financial adviser or in any other fiduciary capacity with respect to any transaction presented to you. Any transaction(s) or products(s) mentioned herein may not be appropriate for all investors and before entering into any transaction you should take steps to ensure that you fully understand such transaction(s) and have made an independent assessment of the appropriateness of the transaction(s) in the light of your own objectives and circumstances, including the possible risks and benefits of entering into such transaction. You should also consider seeking advice from your own advisers in making this assessment. If you decide to enter into a transaction with DWS Group you do so in reliance on your own judgment. The information contained in this document is based on material we believe to be reliable; however, we do not represent that it is accurate, current, complete, or error free. Assumptions, estimates and opinions contained in this document constitute our judgment as of the date of the document and are subject to change without notice. Any projections are based on a number of assumptions as to market conditions and there can be no guarantee that any projected results will be achieved. Past performance is not a guarantee of future results. The distribution of this document and availability of these products and services in certain jurisdictions may be restricted by law. You may not distribute this document, in whole or in part, without our express written permission.

For investors in Bermuda: This is not an offering of securities or interests in any product. Such securities may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation.

© 2024 DWS Investment GmbH, Mainzer Landstraße 11-17, 60329 Frankfurt am Main, Germany.
All rights reserved.